ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Abstract Number: 0159

Understanding the Economic Impact of Autoimmune Eye Disease in the United States
Abstract Number: 0160

Spine and Sacroiliac Joints Findings in Young Males and Females with Chronic Back Pain Undergoing Magnetic Resonance Imaging in Clinical Practice
Abstract Number: 0161

Differences and Similarities Between the EULAR/ASAS-EULAR Recommendations and National Recommendations for Treatment of Patients with Psoriatic Arthritis and Axial Spondyloarthritis Across Europe
Abstract Number: 0162

Assessing Reproductive Health Counseling and Provider Attitudes in Rheumatology Post Roe v. Wade in Houston, Texas
Abstract Number: 0163

Uncovering Discrepancies: Analysis of Glucocorticoid Exposure Among Patients with Rheumatoid Arthritis in Electronic Health Record Data versus Medicare Claims
Abstract Number: 0164

Development and Validation of a Virtual Musculoskeletal Examination Method for Disease Activity Assessment in Rheumatoid Arthritis Patients
Abstract Number: 0165

Hypothyroidism Is Associated with Worse Clinical and Utilization Outcomes After Primary Total Knee Arthroplasty
Abstract Number: 0166

Annual Economic Burden for Patients with Familial Hypophosphatemia in the United States
Abstract Number: 0167

Healthcare Resource Utilization Associated with Tumor-Induced Osteomalacia: Review of Patient Histories Prior to Entry in Clinical Trial UX023T-CL201
Abstract Number: 0168

What Are the Characteristics of a Cost-Effective Psoriatic Arthritis Biomarker Test? An Early Health Technology Assessment
Abstract Number: 0169

Added Value of Anti-HMGCR and Anti-SRP Antibodies in the Diagnosis of Immune Mediated Necrotizing Myopathy: An Outcome and Cost Comparison from the USA Perspective
Abstract Number: 0170

Gender Equity Amongst Rheumatology Professionals: Preliminary Findings of the Coalition for Health and Gender Equity E-survey (CHANGE Group)
Abstract Number: 0171

A Conceptual Framework to Characterize the Indirect Burden of Systemic Lupus Erythematosus (SLE): Findings from Qualitative Patient Interviews
Abstract Number: 0172

Barriers and Strategies to Enhance Patient Research Partner Involvement in Rheumatology Research: A Systematic Literature Review
Abstract Number: 0173

Review of Published Literature Reporting Economic Burden of Treatment Switching in Rheumatoid Arthritis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].